Effects of Levothyroxine Replacement Therapy on Parameters of Metabolic Syndrome and Atherosclerosis in Hypothyroid Patients: A Prospective Pilot Study

Table 1

Basic clinical parameters in control and hypothyroid patients before (HypoT) and after treatment with LT4 (LT4).

Basic clinical parameters	Study groups			value; (-test)
	Control	HypoT	LT4
Age year; ± SD (min–max)	44 ± 10; (29–61)	49 ± 10; (28–64)	49 ± 10; (28–64)	N.S.
BMI kg/m^2; ± SD (min–max)	25.65 ± 2.9; (21.5–38.9)	28.47 ± 4.1 (21.6–37.9)	27.68 ± 4.0 (20.2–36.4)	<0.05^*; <0.001^###
SBP mmHg; ± SD (min–max)	121 ± 14; (100–150)	138 ± 25; (100–210)	118 ± 17; (90–170)	<0.01^**; <0.001^###
DBP mmHg; ± SD (min–max)	80 ± 10; (70–100)	88 ± 13; (70–120)	74 ± 9; (60–100)	<0.05^*; <0.001^###

BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HypoT: hypothyroid patients, and LT4: patients after treatment with LT4. Values are given as mean ± SD; ^* < 0.05; ^** < 0.01. * represents significance between control and hypothyroid patients before treatment; ^### < 0.001. # represents significance between hypothyroid patients before and after treatment.